RT Journal Article SR Electronic T1 Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY) JF Journal of Medical Genetics JO J Med Genet FD BMJ Publishing Group Ltd SP 226 OP 236 DO 10.1136/jmedgenet-2019-106407 VO 57 IS 4 A1 Bancroft, Elizabeth K A1 Saya, Sibel A1 Brown, Emma A1 Thomas, Sarah A1 Taylor, Natalie A1 Rothwell, Jeanette A1 Pope, Jennifer A1 Chamberlain, Anthony A1 Page, Elizabeth A1 Benafif, Sarah A1 Hanson, Helen A1 Dias, Alexander A1 Mikropoulos, Christos A1 Izatt, Louise A1 Side, Lucy A1 Walker, Lisa A1 Donaldson, Alan A1 Cook, Jackie A A1 Barwell, Julian A1 Wiles, Vicki A1 Limb, Lauren A1 Eccles, Diana M A1 Leach, Martin O A1 Shanley, Susan A1 Gilbert, Fiona J A1 Gallagher, David A1 Rajashanker, Balashanmugam A1 Whitehouse, Richard W A1 Koh, Dow-Mu A1 Sohaib, S Aslam A1 Evans, D Gareth A1 Eeles, Rosalind A A1 Walker, Leslie G YR 2020 UL http://jmg.bmj.com/content/57/4/226.abstract AB Background Germline TP53 gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening is recommended for female TP53 pv carriers. The SIGNIFY study (Magnetic Resonance Imaging screening in Li Fraumeni syndrome: An exploratory whole body MRI) study reported outcomes of whole-body MRI (WB-MRI) in a cohort of 44 TP53 pv carriers and 44 matched population controls. The results supported the use of a baseline WB-MRI screen in all adult TP53 pv carriers. Here we report the acceptability of WB-MRI screening and effects on psychosocial functioning and health-related quality of life in the short and medium terms.Methods Psychosocial and other assessments were carried out at study enrolment, immediately before MRI, before and after MRI results, and at 12, 26 and 52 weeks’ follow-up.Results WB-MRI was found to be acceptable with high levels of satisfaction and low levels of psychological morbidity throughout. Although their mean levels of cancer worry were not high, carriers had significantly more cancer worry at most time-points than controls. They also reported significantly more clinically significant intrusive and avoidant thoughts about cancer than controls at all time-points. There were no clinically significant adverse psychosocial outcomes in either carriers with a history of cancer or in those requiring further investigations.Conclusion WB-MRI screening can be implemented in TP53 pv carriers without adverse psychosocial outcomes in the short and medium terms. A previous cancer diagnosis may predict a better psychosocial outcome. Some carriers seriously underestimate their risk of cancer. Carriers of pv should have access to a clinician to help them develop adaptive strategies to cope with cancer-related concerns and respond to clinically significant depression and/or anxiety.